122 related articles for article (PubMed ID: 15327409)
1. Transferrin saturation with intravenous irons: an in vitro study.
Agarwal R
Kidney Int; 2004 Sep; 66(3):1139-44. PubMed ID: 15327409
[TBL] [Abstract][Full Text] [Related]
2. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
3. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
4. Labile iron in parenteral iron formulations: a quantitative and comparative study.
Van Wyck D; Anderson J; Johnson K
Nephrol Dial Transplant; 2004 Mar; 19(3):561-5. PubMed ID: 14767009
[TBL] [Abstract][Full Text] [Related]
5. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.
Zanen AL; Adriaansen HJ; van Bommel EF; Posthuma R; Th de Jong GM
Nephrol Dial Transplant; 1996 May; 11(5):820-4. PubMed ID: 8671901
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Release Kinetics and Transferrin Saturation Study of Intravenous Iron Sucrose Entrapped in Poly(ethylene glycol)-Assisted Silica Xerogel.
Jha J; Chakraborty S; Chaudhuri MG; Dey R
Appl Biochem Biotechnol; 2016 Apr; 178(7):1351-62. PubMed ID: 26686338
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients.
Folkert VW
Nephrol Nurs J; 2003 Oct; 30(5):571-6, 584. PubMed ID: 14621635
[TBL] [Abstract][Full Text] [Related]
8. Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
Warady BA; Seligman PA; Dahl NV
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1140-6. PubMed ID: 17942782
[TBL] [Abstract][Full Text] [Related]
9. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease.
Agarwal R; Rizkala AR; Kaskas MO; Minasian R; Trout JR
Kidney Int; 2007 Sep; 72(5):638-42. PubMed ID: 17622274
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
Adhikary L; Acharya S
JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
[TBL] [Abstract][Full Text] [Related]
11. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
[TBL] [Abstract][Full Text] [Related]
12. Parenteral iron use in the management of anemia in end-stage renal disease patients.
Bailie GR; Johnson CA; Mason NA
Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
14. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
15. Parenteral iron therapy options.
Silverstein SB; Rodgers GM
Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
[TBL] [Abstract][Full Text] [Related]
16. Parenteral iron nephrotoxicity: potential mechanisms and consequences.
Zager RA; Johnson AC; Hanson SY
Kidney Int; 2004 Jul; 66(1):144-56. PubMed ID: 15200421
[TBL] [Abstract][Full Text] [Related]
17. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
18. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
